login

Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival

The American Journal of MedicinePublished 1 March 2001
Kevin Flaherty, Galen B. Toews, Joseph P. Lynch, Ella A. Kazerooni, Barry H. Gross, Robert L. Strawderman
Citations180
SJR quartileQ1
SJR score1.00
SNIP1.04

TL;DR

Coricosteroid treatment for idiopathic pulmonary fibrosis is associated with substantial morbidity and patients who remain stable or respond to corticosteroid therapy have better survival than those who fail to respond.

Abstract

Corticosteroid treatment for idiopathic pulmonary fibrosis is associated with substantial morbidity. Patients who remain stable or respond to corticosteroid therapy have better survival than those who fail to respond. Whether this difference reflects an effect of treatment or less severe disease can be determined only in a randomized trial.

Keywords

Medicine